FASLG and prostate carcinoma: Herein, we used human cervix and prostate carcinoma cells as a model system for DR-triggered apoptosis to interrogate whether miR-133b is capable of modifying the cellular death response to TNFα, Fas/CD95 ligand (FasL) or TRAIL.